Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Imaging Schedule Following CRT in Locally Advanced NSCLC

February 26th 2019

The Role of Surgery in NSCLC Following PACIFIC Trial

February 26th 2019

Impact of PACIFIC Trial on Locally Advanced NSCLC

February 26th 2019

Process Gets Overlooked in the Obsession With Outcomes in Oncology

February 14th 2019

It is essential to appreciate that precision cancer medicine is a process, not an event.

Microbial Metabolomics: A Search for the Missing Link to Cancer

February 8th 2019

Thanks to technological advances, the past several decades have witnessed a blossoming appreciation of the varied composition of these microbial communities, their complex and dynamic relationship with the host, and the way they affect health and disease.

Cristofanilli Explains Precision of Liquid Biopsies in Advanced Breast Cancer

February 7th 2019

Massimo Cristofanilli, MD, discusses the clinical utility of liquid biopsies—specifically focusing on circulating tumor cells and cell-free DNA—and highlights ongoing research in the space.

cfDNA Cancer Detection Remains Viable, But Requires Further Validation

February 6th 2019

Geoffrey R. Oxnard, MD, discusses the use of cell-free DNA as a potential method of cancer detection and subsequent assessment of treatment response in patients with solid and hematologic malignancies.

Further Evidence Needed Supporting Clinical Utility of Liquid Biopsies in GI Cancers

February 5th 2019

John Strickler, MD, discusses how liquid biopsies are being used to help guide treatment decisions for patients with GI cancers and shed light on other research efforts that are being made to improve outcomes.

Lung-MAP Trial Expands to Include All Patients With NSCLC

January 30th 2019

The Lung Cancer Master Protocol, known as the first precision medicine trial in lung cancer supported by the National Cancer Institute, has expanded to include patients with all types of non–small cell lung cancers.

Dr. Sparano on Improving Liquid Biopsies in Breast Cancer

January 30th 2019

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses ways to improve the clinical utility of liquid biopsies in the treatment of patients with breast cancer.

Novel Agents Aimed at Disrupting Cancer Metabolism Gain Ground

January 25th 2019

Since the Warburg effect has been observed in the majority of cancer types, many studies have focused on developing therapies that target metabolic pathways.

Sequencing Therapy in ALK+ NSCLC

January 14th 2019

Biopsy Considerations After Progression in ALK+ NSCLC

January 14th 2019

Treating Newly Diagnosed ALK+ NSCLC

January 14th 2019

Systemic Therapy Vs Radiotherapy for Small Brain Mets

January 14th 2019

Treatment of EGFR+ NSCLC After Osimertinib

January 14th 2019

Frontline Treatment for EGFR+ NSCLC

January 14th 2019

NSCLC: Treating Progression After Chemo and I-O

January 14th 2019

TMB and Multiplex Testing in Metastatic NSCLC

January 14th 2019

Combinations With Novel Agents for Metastatic NSCLC

January 14th 2019